Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study. [electronic resource]
Producer: 20111220Description: 1720-6 p. digitalISSN:- 1029-2403
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- therapeutic use
- Argentina
- Benzamides
- Disease Progression
- Drug Resistance, Neoplasm -- genetics
- Female
- Fusion Proteins, bcr-abl -- genetics
- Humans
- Imatinib Mesylate
- Kaplan-Meier Estimate
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Male
- Middle Aged
- Mutation -- genetics
- Piperazines -- therapeutic use
- Pyrimidines -- therapeutic use
- Treatment Outcome
- Young Adult
No physical items for this record
Publication Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.